QQ客服 官方微博 反馈留言

	PLGA-lecthin-PEG-folate Core-shell Nanoparticles for Cisplatin-prodrug Targeted Delivery
	Mingbin Zheng; Ping Gong; Dongxue Jia; Yangyang Lu; Cuifang Zheng; Pengfei Zhao; Lintao Cai
	2015
会议名称	ChinaNanomedicine 2015
会议地点	Hangzhou, China
英文摘要	Cisplatin is one of the most widely used agents in the treatment of a variety of tumors. However, its toxicity, cross-resistance, and poor targeting limit application of cisplatin. Furthermore its hydrophilic makes it difficult to encapsulate in nanoparticles (NPs) that maintain adequate concentrations for long time periods. In this report, we applied a cisplatin-prodrug (c,c,t-[Pt(NH3)2Cl2(O2CCH2CH2CH2CH2CH3)2]) approach to enhance cisplatin hydrophobicity，using poly(lactic-co-glycolic acid)（PLGA-lecithin-polyethylene glycol(PEG)-folate(FA) core-shell NPs as the drug carrier. The cisplatin-prodrug loaded PLGA-lecithin-PEG-FA NPs (FA-CPNPs) with different cisplatin-prodrug/PLGA weight ratio had the mean size of 109～122 nm, zeta potentional of -26～-33 mV and polydispersity index of 0.1～0.2 very closed to that of original “empty” NPs. Incorporation of prodrug into PLGA-lecithin-FA NPs enhanced substantially encapsulation efficiency of cisplatin. FA-CPNPs had a much higher uptake rate in MCF-7 cells and accumulation in MCF-7 xenograft tumor than free cisplatin. The cell survival rate assays in vitro and chemotherapy in vivo indicated that the FA-CPNPs could efficiently suppressed MCF-7 cells and xenograft tumor. No noticeable abnormality was observed in heart, liver, spleen, lung and kidneys after the intravenous injection of FA-CPNPs. Our study provided the experiment evidence for the development of novel, effective and safety formulations of platinum drugs.
收录类别	其他
语种	英语
内容类型	会议论文
源URL	[http://ir.siat.ac.cn:8080/handle/172644/7435]
专题	深圳先进技术研究院_医药所
作者单位	2015
推荐引用方式 GB/T 7714	Mingbin Zheng,Ping Gong,Dongxue Jia,et al. PLGA-lecthin-PEG-folate Core-shell Nanoparticles for Cisplatin-prodrug Targeted Delivery[C]. 见:ChinaNanomedicine 2015. Hangzhou, China.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。